Efficacy News and Research

RSS

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Allergies common in ADHD, tic disorder patients

A significant number of people with attention deficit/hyperactivity disorder and tic disorder also have one or more allergic diseases such as asthma or atopic dermatitis, show study results.

23 Nov 2012

Rheumatoid arthritis patients adhere to both adalimumab, etanercept

Patients with active rheumatoid arthritis are as likely to persist with adalimumab treatment as they are with etanercept, show the results of a 2-year randomized efficacy and discontinuation study of the two tumor necrosis factor inhibitors.

23 Nov 2012

Temsirolimus effective for mRCC patients on hemodialysis

Research findings published in the International Journal of Clinical Oncology suggest that temsirolimus effectively stabilizes disease progression in patients with metastatic renal cell carcinoma undergoing hemodialysis.

22 Nov 2012

Bipolar I disorder has higher costs than other affective disorders

Results from an Australian study show that bipolar I disorder is associated with higher costs than bipolar II disorder or unipolar depression.

22 Nov 2012

Citicoline not superior to placebo in treating traumatic brain injury

Although approved for use for treating traumatic brain injury (TBI) in nearly 60 countries, use of citicoline in a randomized trial that included more than 1,200 participants with TBI did not result in improvement in functional and cognitive status, according to a study appearing in the November 21 issue of JAMA.

22 Nov 2012

Australian TGA approves Genzyme’s AUBAGIO to treat relapsing forms of multiple sclerosis

Genzyme, a Sanofi company, announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

21 Nov 2012

Prader-Willi children may receive relief from sleep disorders after adenotonsillectomy

Children with Prader-Willi syndrome may receive relief from sleep disorders after undergoing an adenotonsillectomy, suggests a new study from Nationwide Children's Hospital published in the November print issue of the Archives of Otolaryngology-Head and Neck Surgery.

21 Nov 2012

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

Alzheimer's therapeutic trials have gotten bad press lately, but it is not all gloom and doom. As evident at the 5th Clinical Trials in Alzheimer's Disease (CTAD) conference, held 29-31 October in the Principality of Monaco, scientists keep extracting new data from recent drug trials to gear up for a round of new ones that aim to tackle Alzheimer's earlier than ever before.

21 Nov 2012

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.

21 Nov 2012

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Bristol-Myers Squibb and Pfizer announced today that the European Commission has approved ELIQUIS (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors.

21 Nov 2012

New polymer-based system to fight infection, filter water and heal wounds

Working in the lab for the last few years, three generations of University of Akron polymer scientists say their mutual and passionate curiosity about science has led to their discovery of a first-of-its-kind, easily adaptable biocompatible polymer structure able to fight infection, filter water and perform a host of other functions.

20 Nov 2012

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

St. Jude Medical’s Portico transcatheter heart valve receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval for its 23 mm Portico Transcatheter Aortic Heart Valve and Transfemoral Delivery System.

20 Nov 2012

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).

19 Nov 2012

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.

19 Nov 2012

New bulimia nervosa therapy for patients with eating disorders

An eating disorders research team led by Stephen Wonderlich, a Director of Clinical Research at the Neuropsychiatric Research Institute (NRI), has developed a successful bulimia nervosa therapy that can provide patients an alternative for treating this debilitating disorder.

18 Nov 2012

Two studies investigate role of oxygen in cell transplantation

Two studies published in the current issue of Cell Transplantation, now freely available on-line, investigate the role of oxygen in cell transplantation.

17 Nov 2012

Interim results from RTS,S vaccine on-going phase III trial on malaria

According to the World Health Organization (WHO), more than 250 million clinical malaria cases are attributed to Plasmodium falciparum (Pf) annually, with over 1.1 million deaths in sub-Saharan Africa alone.

17 Nov 2012

Efficacy News and Research

mRNA vaccines offer protection against influenza A virus infections in various animal models

Allergies common in ADHD, tic disorder patients

Rheumatoid arthritis patients adhere to both adalimumab, etanercept

Temsirolimus effective for mRCC patients on hemodialysis

Bipolar I disorder has higher costs than other affective disorders

Citicoline not superior to placebo in treating traumatic brain injury

Australian TGA approves Genzyme’s AUBAGIO to treat relapsing forms of multiple sclerosis

Prader-Willi children may receive relief from sleep disorders after adenotonsillectomy

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

New polymer-based system to fight infection, filter water and heal wounds

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

St. Jude Medical’s Portico transcatheter heart valve receives European CE Mark approval

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

New bulimia nervosa therapy for patients with eating disorders

Two studies investigate role of oxygen in cell transplantation

Interim results from RTS,S vaccine on-going phase III trial on malaria

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News